Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
assistant). About the research training As a PhD Research Fellow, you must participate in an approved educational programme for a PhD degree within a period of 3 years. The deadline for applying for admission
-
previously been employed in a qualifying post (e.g. research fellow, research assistant). About the research training As a PhD Research Fellow, you must participate in an approved educational programme for a
-
confirming receipt of your application. Please note that the automatic recognition offered by HK-dir insufficient and will not be accepted as basis for admission to the PhD programme. Applicants with education
-
of your application. Please note that the automatic recognition offered by HK-dir insufficient and will not be accepted as basis for admission to the PhD programme. Applicants with education from a Nordic
-
of results and university administration. A plan for this part of the position will be established in collaboration with the Department. As a PhD candidate, you must participate in the Faculty of Humanities
-
to the research project itself is 2.5 years, whilst a total of one year will be devoted to other, career-promoting work such as teaching, dissemination of results and university administration. A plan for this part
-
integrated masters’ program in pharmacy and contribute to professional development for pharmacy students and teaching in social pharmacy / pharmacy practice. The candidate will belong to, and have a vital role
-
a PhD Research Fellow, you must participate in an approved educational programme for a PhD degree within a period of 3 years. The deadline for applying for admission to the PhD programme at
-
fellow, research assistant). About the research training As a PhD Research Fellow, you must participate in an approved educational programme for a PhD degree within a period of 3 years. The deadline
-
by the EU programme Horizon Europe. The main aim of the project is to unveil the role of the Epstein-Barr virus (EBV) in the onset and progression of the Multiple Sclerosis (MS) disease. The position